The CHADS-VASc score is a predictor of no-reflow in patients with non-ST-segment elevation myocardial infarction
Date
2020Author
Gungor, Baris
Isleyen, Hasan Burak
Okuyan, Ertugrul
Yildirim, Mehmet Rifat
Sahin, Irfan
Barman, Hasan Ali
Kahyaoglu, Serdar
DURMAZ, Eser
Atici, Adem
Gulsen, Kamil
Tugrul, Sevil
Metadata
Show full item recordAbstract
This study was performed to evaluate the relationship between the CHA(2)DS(2)-VASc score and no-reflow (NR) phenomena in patients with non-ST-segment elevation myocardial infarction (NSTEMI). A total number of 428 consecutive patients with NSTEMI were assessed for this study. Patients were divided into 2 groups, those with NR, NR(+) (n=84), and those without NR, NR(-) (n=307), according to their post-PCI, no-reflow status. The CHA(2)DS(2)-VASc score was significantly higher in the NR(+) group compared to the NR(-) (3.48 +/- 1.19 vs 1.81 +/- 0.82,P< 0.001). After a multivariate regression analysis, a higher CHA(2)DS(2)-VASc score (OR: 6.52, 95% CI: 3.51-12.14,P< 0.001), hs-Troponin (OR: 1.077, 95% CI: 1.056-1.099,P<0.001) and TTG (OR: 1.563, 95% CI: 1.134-2.154,P=0.006) were independent predictors of NR. CHA(2)DS(2)-VASc score is associated with higher risk of no-reflow in patients with NSTEMI undergoing PCI.
Collections
- Makale [92796]